Biocon has received approval from the European Medicines Agency (EMA) for a new drug product fill finish line for Semglee (insulin glargine) at its insulin manufacturing facility in Malaysia. Supplies to Europe from this line are expected to begin from Q2FY27.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.